|
DIAGNOSIS AND SURVEILLANCE OF INDETERMINATE PULMONARY NODULES -ACR ACRIN
(4703) CT
Description: The main objective of this trial is to improve the efficiency of the diagnostic evaluation of patients with indeterminate pulmonary nodules. The trial will determine the diagnostic accuracy of biomarkers for lung cancer measured in minimally-invasive and non-invasive biospecimens, and whether these genomic and proteomic biomarkers in the airway and blood can distinguish between high-risk smokers with malignant or benign indeterminate, incidentally-detected pulmonary nodules.
Participants: Patients enrolled will be 45 years or older, have been diagnosed with indeterminate pulmonary nodules within the year prior to enrollment (size at time of consent must be: 0.7 to 3.0 cm), and have a smoking status as a current or former smoker with ≥20 pa
Disease Site: Lung
Response Endpoint/TX: NA
Modality: CT
URL :
http://www.clinicaltrials.org/
|
Restricted-use dataset
354 cases
|
|
|
SCREENING OF PTS WITH EARLY STAGE LUNG CA OR AT HIGH RISK FOR DEVELOPING LUNG CA -ACR ACRIN
(4704) CT
Description: The main objectives of this study are to a) discover new biomarkers in early stage lung cancer for use in diagnosis of disease and b) discover new genomic and proteomic biomarkers in the airway and blood for preclinical detection of lung cancer among people at high risk of
developing lung cancer.
Participants: Participants will be recruited to one of two cohorts for the DECAMP-2 study:
a) the cross-sectional cohort, Group A, which will comprise approximately 80 patients planned
to go to resection surgery due to recently-diagnosed early stage lung cancer or susp
Disease Site: Lung
Response Endpoint/TX: NA
Modality: CT
URL :
http://www.clinicaltrials.org/
|
Restricted-use dataset
396 cases
|
|
DIGITAL MAMMOGRAPHY -Legacy ACRIN
(6652) MG
Description: To compare the diagnostic performance of digital mammography and screen-film mammography, as measured by the area under the ROC curve, sensitivity, specificity, and positive and negative predictive values in a prospectively enrolled screening cohort of asymptomatic women, across all digital mammography machine types.
Participants: Asymptomatic women presenting for screening mammography will be enrolled into this trial at 34 centers in the U.S. and Canada.
Disease Site: Breast
Response Endpoint/TX: Detection
Modality: Dig Mammogram
URL :
http://www.clinicaltrials.org/
|
Safe harbor dataset
40895 cases
|
|
|
CONTEMPORARY SCREENING FOR THE DETECTION OF LUNG CANCER:PRE-MALIG AND MALIG -Legacy ACRIN
(6654) CT
Description: To determine whether lung cancer screening using low-dose helical CT reduces lung cancer-specific mortality relative to screening with chest radiographs in a high-risk cohort
Participants: Current or former cigarette smokers between the ages of 55 and 74 years without a history of lung cancer
Disease Site: Lung
Response Endpoint/TX: Detection
Modality: CT
URL :
http://www.clinicaltrials.org/
|
Restricted-use dataset
18894 cases
|
|
NLST with Cancer data access system (CDAS) IDs -Legacy ACRIN
(6654CDAS) X-RAY
Description: X-ray images from NLST mapped to CDAS case numbers
Participants: NA
Disease Site: Chest
Response Endpoint/TX: early detection of lung cancer CTs vs X-Rays
Modality: X-RAY
URL :
NA
|
Safe harbor dataset
5491 cases
|
|
|
MRI EVALUATION OF STAGE III BREAST PATIENTS -Legacy ACRIN
(6657) MR
Description: Use MRI measurements of tumor response to uniquely identify two groups of participants who have statistically different three-year disease-free survival out of a group of participants with Stage III breast cancer who demonstrate a partial or minimal clinical response (as identified by physical examination) to neoadjuvant chemotherapy.
The objective of the ACRIN 6657 protocol extension is to investigate the usefulness of total choline concentration [tCho] measured by 1H MRS early in the course of treatment, for predicting pathologic response. Following completion of accrual to the original 6657 protocol, an additional group of patients meeting the same eligibility criteria as in the original protocol are being enrolled to the protocol extension. Three changes to the imaging protocol have been made: 1) addition of a single voxel 1H MRS acquisition and optional diffusion-weighted MRI acquisition to the MRI exam, 2) reduction of the number of (6657 study-related) imaging exams from 4 to 3 during the course of treatment, and 3) change of the timing of the post 1st cycle MRI/MRS exam.
Participants: Participants enrolled in the CALGB/Intergroup trial 49808 or participants receiving neoadjuvant chemotherapy consisting of an anthracyclin based regimen only or followed by a taxane and enrolled in CALGB Correlative Science trial 150007.
Disease Site: Breast
Response Endpoint/TX: Pathologic Response/ Chemotherapy
Modality: Serial Breast MRI (1273 studies)
URL :
http://www.clinicaltrials.org/
|
Restricted-use dataset
356 cases
|
|
|
MRI EVALUATION OF STAGE III BREAST PATIENTS -Legacy ACRIN
(6657) MR
Description: Use MRI measurements of tumor response to uniquely identify two groups of participants who have statistically different three-year disease-free survival out of a group of participants with Stage III breast cancer who demonstrate a partial or minimal clinical response (as identified by physical examination) to neoadjuvant chemotherapy.
The objective of the ACRIN 6657 protocol extension is to investigate the usefulness of total choline concentration [tCho] measured by 1H MRS early in the course of treatment, for predicting pathologic response. Following completion of accrual to the original 6657 protocol, an additional group of patients meeting the same eligibility criteria as in the original protocol are being enrolled to the protocol extension. Three changes to the imaging protocol have been made: 1) addition of a single voxel 1H MRS acquisition and optional diffusion-weighted MRI acquisition to the MRI exam, 2) reduction of the number of (6657 study-related) imaging exams from 4 to 3 during the course of treatment, and 3) change of the timing of the post 1st cycle MRI/MRS exam.
Participants: Participants enrolled in the CALGB/Intergroup trial 49808 or participants receiving neoadjuvant chemotherapy consisting of an anthracyclin based regimen only or followed by a taxane and enrolled in CALGB Correlative Science trial 150007.
Disease Site: Breast
Response Endpoint/TX: Pathologic Response/ Chemotherapy
Modality: Serial Breast MRI (1273 studies)
URL :
http://www.clinicaltrials.org/
|
Safe harbor dataset
220 cases
|
|
NATIONAL CT COLONOGRAPHY -Legacy ACRIN
(6664) CT
Description: To clinically validate widespread use of computerized tomographic colongraphy (CTC) in a screening population for the detection of colorectal neoplasia.
Participants: Male and female outpatients, aged 50 years or older, scheduled for screening colonoscopy, who have not had a colonoscopy in the past 5 years.
Disease Site: Gastrointestinal
Response Endpoint/TX: NA
Modality: CT
URL :
NA
|
Safe harbor dataset
2617 cases
|
|
|
MRI EVALUATION OF CONTRALATERAL BREAST -Legacy ACRIN
(6667) MR
Description: To determine the cancer yield of MRI in the contralateral breast of women with a recent breast cancer diagnosis and no known disease by mammography or clinical breast exam in the contralateral breast.
Participants: A total of 1,007 women with a recent history of breast cancer (negative or benign mammogram, and negative or benign clinical breast exam of the contralateral breast within 60 days prior to enrollment) will be enrolled into the trial at 22 centers in the U
Disease Site: Breast
Response Endpoint/TX: Detection
Modality: MRI
URL :
http://www.clinicaltrials.org/
|
Restricted-use dataset
1007 cases
|
|
|
MRI EVALUATION OF CONTRALATERAL BREAST -Legacy ACRIN
(6667) MR
Description: To determine the cancer yield of MRI in the contralateral breast of women with a recent breast cancer diagnosis and no known disease by mammography or clinical breast exam in the contralateral breast.
Participants: A total of 1,007 women with a recent history of breast cancer (negative or benign mammogram, and negative or benign clinical breast exam of the contralateral breast within 60 days prior to enrollment) will be enrolled into the trial at 22 centers in the U
Disease Site: Breast
Response Endpoint/TX: NA
Modality: NA
URL :
NA
|
Safe harbor dataset
1007 cases
|
|
|
POSITRON EMISSION TOMOGRAPHY PRE-AND POST-TREATMENT -Legacy ACRIN
(6668) PT/CT
Description: The primary purpose of this study is to determine if the SUV measurement from FDG-PET imaging shortly after treatment is a useful predictor of long-term clinical outcome (survival) after definitive chemoradiotherapy.
Participants: Eligible patients are those older than 18 years with AJCC clinical stage IIB/III non-small cell lung carcinoma who are being planned for definitive concurrent chemoradiotherapy (inoperable disease).
Disease Site: Lung
Response Endpoint/TX: NA
Modality: PET
URL :
NA
|
Safe harbor dataset
251 cases
|
|
|
POSITRON EMISSION TOMOGRAPHY PRE-AND POST-TREATMENT -Legacy ACRIN
(6668) PT/CT
Description: The primary purpose of this study is to determine if the SUV measurement from FDG-PET imaging shortly after treatment is a useful predictor of long-term clinical outcome (survival) after definitive chemoradiotherapy.
Participants: Eligible patients are those older than 18 years with AJCC clinical stage IIB/III non-small cell lung carcinoma who are being planned for definitive concurrent chemoradiotherapy (inoperable disease)
Disease Site: Lung
Response Endpoint/TX: Response, PFS, OS/ Rad Therapy
Modality: Serial FDG PET/CT (840 studies)
URL :
http://www.clinicaltrials.org/
|
Restricted-use dataset
251 cases
|
|
RTOG 0625/ACRIN 6677 -Legacy ACRIN
(6677) MR
Description: For central review -- to assess the agreement between local interpretation and central interpretation of the standard MRI on the 6-month progression-free survival and to estimate the accuracy of local interpretation on the 6-month progression-free survival using central review as the reference standard.
Participants: Persons 18 years and older with a histologically proven intracranial glioblastoma or gliosarcoma. There must be pathologic or imaging confirmation of tumor progression or regrowth.
Disease Site: Brain
Response Endpoint/TX: PFS, OS/Rad Therapy, Chemotherapy, Anti-vascular agents
Modality: Serial MRI (537 studies)/MRs
URL :
http://www.clinicaltrials.org/
|
Restricted-use dataset
123 cases
|
|
|
RTOG 0625/ACRIN 6677 -Legacy ACRIN
(6677) MR
Description: For central review -- to assess the agreement between local interpretation and central interpretation of the standard MRI on the 6-month progression-free survival and to estimate the accuracy of local interpretation on the 6-month progression-free survival using central review as the reference standard.
Participants: Persons 18 years and older with a histologically proven intracranial glioblastoma or gliosarcoma. There must be pathologic or imaging confirmation of tumor progression or regrowth.
Disease Site: Brain
Response Endpoint/TX: PFS, OS/Rad Therapy, Chemotherapy, Anti-vascular agents
Modality: Serial MRI (537 studies)/MRs
URL :
http://www.clinicaltrials.org/
|
Safe harbor dataset
123 cases
|
|
|
ASSESSMENT OF TUMOR HYPOXIA IN GLIOBLASTOMA WITH PET AND MRI -Legacy ACRIN
(6684) MR
Description: To determine the association of baseline FMISO PET uptake
(tumor to blood ratio, hypoxic volume) and MRI parameters (Ktrans, CBV) with overall survival, time to disease progression, and 6-month progression free survival in participants with newly diagnosed glioblastoma (GBM).
Participants: A total of 50 participants will be enrolled. A subset of 15 participants will have test-retest FMISO PET scans at baseline performed between 1 and 7 days apart (both scans completed prior to initiation of chemoradiation). Each institution will not enrol
Disease Site: Brain
Response Endpoint/TX: PFS, OS/Rad Therapy, Chemotherapy
Modality: FMISO (44)DCE MRI (47)DSC MRI (47) MRS (37)
URL :
http://www.clinicaltrials.org/
|
Safe harbor dataset
50 cases
|
|
|
FDG PET/CT STAGING OF HEAD AND NECK CANCER AND ITS IMPACT ON THE N0 NECK -Legacy ACRIN
(6685) Multi-modality
Description: The objective of this study is to determine the negative predictive value of PET/CT for the N0 neck based upon pathologic sampling of the neck lymph nodes and to determine PET/CT’s potential to change treatment of the N0 neck.
Participants: NA
Disease Site: NA
Response Endpoint/TX: NA
Modality: Multi-modality
URL :
NA
|
Safe harbor dataset
287 cases
|
|
|
PHASE II STUDY OF 3'-DEOXY-3'-18F FLUOROTHYMIDINE (FLT) IN INVASIVE BREAST CNCR -Legacy ACRIN
(6688) PT
Description: To evaluate the relationship between [18F]FLT uptake parameters and pathologic complete response to neoadjuvant therapy of the primary tumor in patients with locally advanced breast cancer.
Participants: NA
Disease Site: Breast
Response Endpoint/TX: Pathologic Response and Tumor KI-67? Chemotherapy
Modality: Serial FLT (199) Serial FDG (19)
URL :
http://www.clinicaltrials.org/
|
Restricted-use dataset
90 cases
|
|
|
PHASE II STUDY OF 3'-DEOXY-3'-18F FLUOROTHYMIDINE (FLT) IN INVASIVE BREAST CNCR -Legacy ACRIN
(6688) PT
Description: To evaluate the relationship between [18F]FLT uptake parameters and pathologic complete response to neoadjuvant therapy of the primary tumor in patients with locally advanced breast cancer.
Participants: NA
Disease Site: Breast
Response Endpoint/TX: Pathologic Response and Tumor KI-67? Chemotherapy
Modality: Serial FLT (199) Serial FDG (19)
URL :
http://www.clinicaltrials.org/
|
Safe harbor dataset
90 cases
|
|
|
ADAPTIVE RT IN LA NSCLC -Legacy ACRIN
(6697) CT
Description: The RTOG 1106/ACRIN 6697 clinical trial is evaluating if during the course of radiotherapy (RT) treatment information gained from a FDG-PET/CT scan can facilitate individualized adaptive therapy in patients with inoperable stage-III non–small-cell lung cancer (NSCLC).
Participants: Patients must be > 18 and have FDG-avid (maximum SUV ≥ 4.0) and histologically
or cytologically proven non-small cell lung cancer.
Disease Site: Lung
Response Endpoint/TX: NA
Modality: CT
URL :
NA
|
Restricted-use dataset
118 cases
|
|
|
AI Stroke -AI Validation
(AIStroke) Multi-modality
Description: GE+MGB CCDS and ACR are teaming up to create a validation n/w solution to test a suite of GE AI Stroke algorithms with data from some potential DSI pilot sites.
Participants: NA
Disease Site: Heart
Response Endpoint/TX: NA
Modality: Multi-modality
URL :
NA
|
Restricted-use dataset
|
|
|
Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) -ALZ-NET
(ALZ-NET) MR, PET
Description: ALZ-NET will collect longitudinal clinical and safety data for enrolled patients treated with novel FDA-approved AD therapies and will track patient long-term health outcomes (effectiveness and safety), associated with use in real-world settings.
Participants: NA
Disease Site: Alzheimer's Disease
Response Endpoint/TX: NA
Modality: MR, PET
URL :
NA
|
Restricted-use dataset
|
|
|
Breast Density Classification Algorithm -BDF Index
(BDF) MG
Description: NA
Participants: NA
Disease Site: Breast
Response Endpoint/TX: NA
Modality: MG
URL :
NA
|
Safe harbor dataset
|
|
|
CANDID-4-AI -ANCIRR
(CANDID) CT
Description: Registry to help clinicians monitor and demonstrate the quality of CT lung cancer screenings in their practice.
Participants: NA
Disease Site: Lung
Response Endpoint/TX: NA
Modality: CT
URL :
NA
|
Safe harbor dataset
|
|
COVID-19 Imaging Research Registry -COVID19
(CIRR) Multi-modality
Description: Registry for accelerating the transfer of knowledge and innovation in the COVID-19 pandemic
Participants: NA
Disease Site: All Body Parts
Response Endpoint/TX: Presence or Absence of Covid-19
Modality: Multi-modality
URL :
NA
|
Restricted-use dataset
|
|
|
COVID-19 Imaging Research Registry -COVID19
(CIRR) Multi-modality
Description: Registry for accelerating the transfer of knowledge and innovation in the COVID-19 pandemic
Participants: NA
Disease Site: All Body Parts
Response Endpoint/TX: Presence or Absence of Covid-19
Modality: Multi-modality
URL :
NA
|
Safe harbor dataset
|
|
|
A Pennsylvania State Multisite Database of Patients with Actionable Focal Masses on Imaging -CURE13
(CURE13 AFM) Multi-modality
Description: The primary aim of this project is to improve patient care through a) implementing standardized radiology report language clearly categorizing masses as benign, indeterminate and suspicious for malignancy and b) creating an automated database that reliably captures all patients with actionable (i.e., indeterminate and suspicious) masses.
Participants: NA
Disease Site: NA
Response Endpoint/TX: Compliance
Modality: Multi-modality
URL :
NA
|
Restricted-use dataset
|
|
|
Test Project for demonstration -TEST
(DEMO) PT
Description: To evaluate the relationship between [18F]FLT uptake parameters and pathologic complete response to neoadjuvant therapy of the primary tumor in patients with locally advanced breast cancer.
Participants: NA
Disease Site: Breast
Response Endpoint/TX: Pathologic Response and Tumor KI-67? Chemotherapy
Modality: Serial FLT (199) Serial FDG (19)
URL :
http://www.clinicaltrials.org/
|
Safe harbor dataset
|
|
|
DSI Test Dataset - MR and CT for LI-RADS -DSI
(DSI Test) CT, MR
Description: Test dataset of CT and MR of the liver
Participants: NA
Disease Site: Liver
Response Endpoint/TX: NA
Modality: Multi-modality
URL :
NA
|
Restricted-use dataset
142 cases
|
|
|
Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma in Situ (DCIS) -ECOG-ACRIN
(E4112) Multi-modality
Description: This clinical trial studies magnetic resonance imaging (MRI) and gene expression in diagnosing patients with abnormal cells in the breast duct that have not spread outside the duct. MRI uses radio waves and a powerful magnet linked to a computer to create detailed pictures of areas inside the body. MRI may help find and diagnose patients with breast cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. Genetic studies may help doctors predict the outcome of treatment and the risk for disease recurrence. Performing MRI with genetic studies may help determine the best treatment for patients with breast cancer in situ.
Participants: NA
Disease Site: Breast
Response Endpoint/TX: NA
Modality: Multi-modality
URL :
NA
|
Restricted-use dataset
368 cases
|
|
|
Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women with Dense Breasts -ECOG-ACRIN
(EA1141) MRI
Description: Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women With Dense Breasts. The study's goal was to evaluate how well abbreviated breast MRI (AB-MRI) and digital breast tomosynthesis (DBT) mammography can detect breast cancer in women with dense breasts.
Participants: The study enrolled 1,516 subjects
Disease Site: Breast
Response Endpoint/TX: NA
Modality: MRI
URL :
https://dart.acr.org/Home/ImagingHub
|
Safe harbor dataset
|
|
|
Molecular Analysis for Therapy Choice (MATCH) -ECOG-ACRIN
(EAY131) Multi-modality
Description: NCI-MATCH is a phase II precision medicine trial that seeks to determine whether matching certain drugs or drug combinations in adults whose tumors have specific gene abnormalities will effectively treat their cancer, regardless of their cancer type.
Participants: About 5000 patients will receive genetic testing to identify those eligible for one of 24 or more treatment options.
Disease Site: All Body Parts
Response Endpoint/TX: NA
Modality: Multi-Modality
URL :
http://ecog-acrin.org/nci-match-eay131
|
Restricted-use dataset
4854 cases
|
|
|
NRG GY006 Radiomics Analysis using PyRadiomics -NRG
(GY006_Mell) PET/CT
Description: To generate radiomic feature sets in DART using PyRadiomics from baseline and 3-month follow-up exams from NRG-GY006
Participants: NA
Disease Site: Gynecologic Cervix
Response Endpoint/TX: NA
Modality: PET/CT
URL :
NA
|
Restricted-use dataset
|
|
|
Normative Neuroimaging Library -HII
(NNL) MR
Description: The Normative Neuroimaging Library addresses major gaps in the optimal utilization of neuroimaging sequences relevant to disorders such as TBI and PTSD through: (i) the collection of age and gender stratified neuroimaging data from normal individuals using standard sequences relevant to disorders such as TBI, PTSD and (ii) establishing optimal standards for normalization of neuroimaging data acquisition between scanners through both hardware-based and image post-processing approaches.
Participants: The NNL will include 3,000 normal particpants between the age of 18 and 65.
Disease Site: Brain
Response Endpoint/TX: NA
Modality: MR
URL :
NA
|
Restricted-use dataset
282 cases
|
|
|
Intracranial Hemorrhage Detection -Assess-AI
(ICH) CT
Description: The objective of the project is to detect intracranial hemorrhage in adult patients.
Participants: NA
Disease Site: Brain
Response Endpoint/TX: Presence or Absence of Intracranial Hemorrage
Modality: CT
URL :
NA
|
Restricted-use dataset
|
|
|
The Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study -IDEAS
(IDEAS) PET
Description: The Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study will determine the clinical usefulness on patient-oriented outcomes of a brain positron emission tomography (PET) scan that detects amyloid plaques, a core feature of Alzheimer’s disease. In addition to assessing the impact of amyloid PET on management of patients with mild cognitive impairment or dementia of uncertain cause, the study will compare medical outcomes for study participants with matched patients not in the study.
Participants: NA
Disease Site: Brain
Response Endpoint/TX: Brain positron emission tomography (PET) scan that detects amyloid plaques
Modality: PET
URL :
NA
|
Safe harbor dataset
15918 cases
|
|
|
Ovarian-Adnexal Reporting & Data System -RADS
(O-RADS) US
Description: To assess the inter-reader agreement for the ACR O-RADS Ultrasound 1-5 score among clinical readers. To assess the inter-reader agreement for the ACR O-RADS Ultrasound score by type of reader: specialist and generalist. To evaluate the effect on using the O-RADS app to the time of getting an O-RADS score and the inter-reader agreement
Participants: NA
Disease Site: Ovarian Cancer
Response Endpoint/TX: NA
Modality: US
URL :
NA
|
Safe harbor dataset
|
|
|
PI-QUAL Prostate Image Quality Assessment Study -RADS
(PI-QUAL) MR
Description: Prostate Image Quality assessment/scoring tool in DART
Participants: NA
Disease Site: Prostate Cancer
Response Endpoint/TX: NA
Modality: MR
URL :
NA
|
Safe harbor dataset
|
|
|
Qualification Utility for the Imaging Core Laboratory -QIN
(QUIC) PT/CT
Description: QUIC project contains data from PET /CT scanner collected by ACRIN's scanner-specific qualification program.
Participants: NA
Disease Site: Phantoms
Response Endpoint/TX: NA
Modality: PET/CT
URL :
NA
|
Restricted-use dataset
348
|
|
|
CT Phantom data from multiple CT scanners -QIN
(CT Phantom) CT
Description: Gammex 464 CT phantom
Participants: NA
Disease Site: All Body Parts
Response Endpoint/TX: NA
Modality: CT
URL :
NA
|
Restricted-use dataset
1972 cases
|
|
|
A Randomized Phase III Comparison of Standard-Dose (60 Gy) Versus High-Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab in Patients With Stage -RTOG
(R0617) RT
Description: A Randomized Phase III Comparison of Standard-Dose (60 Gy) Versus High-Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab in Patients With Stage
Participants: NA
Disease Site: Thoracic
Response Endpoint/TX: NA
Modality: RT
URL :
NA
|
Restricted-use dataset
544 cases
|
|
|
Test Classification Project -Assess-AI
(TCP) CT
Description: Test Classification
Participants: NA
Disease Site: Brain
Response Endpoint/TX: NA
Modality: CT
URL :
NA
|
Restricted-use dataset
|
|
|
Compare ACR TI-RADS to other thyroid ultrasound risk stratification systems in a multi-institutional research registry -TI-RADS
(TI-RADS) US
Description: Compare the proportion of thyroid nodules detected on diagnostics ultrasound that are recommended for biopsy by ACR TI-RADS to other thyroid biopsy guidelines.
Compare the positive predictive value (PPV) of ACR TI-RADS to other thyroid biopsy guidelines.
Participants: Biopsy Outcomes Data: Participating sites will review patient medical records 3-6 months after patients' biopsy encounters. Outcomes data to be collected will include cytology results, molecular testing, subsequent imaging encounters, surgery and final pa
Disease Site: Neck
Response Endpoint/TX: NA
Modality: US
URL :
NA
|
Restricted-use dataset
|
